Description

Horizon Therapeutics Public Limited Company operates as a biotechnology enterprise, primarily concentrating on the identification, refinement, and commercialization of pharmaceutical products designed to address significant medical needs for individuals afflicted by rare, autoimmune, and severe inflammatory conditions. The company's operations are divided into two principal divisions: Orphan and Inflammation. Its extensive product lineup features twelve distinct medications, targeting therapeutic areas such as rare diseases, gout, ophthalmic conditions, and various forms of inflammation. Among its marketed offerings are TEPEZZA (an intravenous infusion), KRYSTEXXA (also administered intravenously), the oral liquid RAVICTI, PROCYSBI (available as oral delayed-release capsules and granules), the subcutaneous injectable ACTIMMUNE, BUPHENYL (oral tablets and powder), the inhaled solution QUINSAIR, and the intravenous injection UPLIZNA. Furthermore, the company's portfolio includes PENNSAID (a topical solution), DUEXIS (oral tablets), RAYOS (delayed-release oral tablets), and VIMOVO (delayed-release oral tablets). Horizon Therapeutics maintains strategic partnerships with several entities, including HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. Founded in 2005, the company, originally known as Horizon Pharma Public Limited Company, rebranded to its current name in May 2019. Its global headquarters are situated in Dublin, Ireland, complemented by additional offices located in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.